Faster Drug Approvals Not Linked To Safety Problems, Says Tufts Study

Drug Industry Daily

Faster drug approvals haven’t led to more safety-related drug withdrawals, says a study by the Tufts Center for the Study of Drug Development (CSDD), even as critics decry the FDA for not protecting consumers in the wake of the Vioxx scandal.

To View This Article:


Subscribe To Drug Industry Daily